Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06414300 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06414300 | EXPERIMENTAL | Participants will receive single or multiple ascending oral doses of PF-06414300 |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo. |
| Name | Type | Description |
|---|---|---|
| PF-06414300 | DRUG | Participants will receive oral ascending doses. |
| Placebo | DRUG | Participants will receive matching placebo. |
Inclusion Criteria: * Body mass Index (BMI) of 16-32 kg/m2; and a total body weight \>50 kg (110 lb). * Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs assessments, 12-lead ECGs a...
PF-06414300 is an investigational small molecule drug developed by Pfizer, Inc. It has been studied in a Phase 1 clinical trial in healthy adult participants. Its intended therapeutic indication has not been disclosed, and it is not approved for any use.
PF-06414300 is made and developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in the United States.
PF-06414300 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational drug and has not been approved by the FDA for any indication.
PF-06414300 has been evaluated in one clinical trial, NCT06659250, titled a study to learn how different amounts and forms of PF-06414300 act in healthy adults. The Phase 1 trial enrolled 63 healthy participants in the United States and is now completed.
The Phase 1 trial NCT06659250 was a randomized, double-blind, placebo-controlled study of PF-06414300 in healthy adult volunteers aged 18 years and older. It enrolled 63 participants across sites in the United States and has been completed.